Q3 Earnings Forecast for SAGE Issued By Leerink Partnrs

Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Stock analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Sage Therapeutics in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman expects that the biopharmaceutical company will earn ($0.15) per share for the quarter. The consensus estimate […]

Leave a Reply

Your email address will not be published.

Previous post Letters to the editor
Next post Q3 Earnings Estimate for Slate Retail REIT Issued By Cormark